Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Bio-Gene Technology's share price for the quarter that ended in Dec. 2023 was A$0.06. Bio-Gene Technology's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 201.36 Mil. Therefore, Bio-Gene Technology's market cap for the quarter that ended in Dec. 2023 was A$12.08 Mil.
Bio-Gene Technology's quarterly market cap
declined
from Dec. 2022 (A$17.79 Mil) to Jun. 2023 (A$13.81 Mil) and
declined
from Jun. 2023 (A$13.81 Mil) to Dec. 2023 (A$12.08 Mil).
Bio-Gene Technology's annual market cap
declined
from Jun. 2021 (A$26.12 Mil) to Jun. 2022 (A$23.28 Mil) and
declined
from Jun. 2022 (A$23.28 Mil) to Jun. 2023 (A$13.81 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Bio-Gene Technology's Enterprise Value for Today is A$10.67 Mil.
Bio-Gene Technology Market Cap Historical Data
The historical data trend for Bio-Gene Technology's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Bio-Gene Technology's Market Cap
For the Biotechnology subindustry, Bio-Gene Technology's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Gene Technology's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Gene Technology's Market Cap distribution charts can be found below:
* The bar in red indicates where Bio-Gene Technology's Market Cap falls into.
Bio-Gene Technology Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Bio-Gene Technology's Market Cap for the fiscal year that ended in Jun. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Gene Technology (ASX:BGT) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Bio-Gene Technology Market Cap Related Terms
Thank you for viewing the detailed overview of Bio-Gene Technology's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Bio-Gene Technology (ASX:BGT) Business Description
Bio-Gene Technology Ltd is an Australian biotechnology company engaged in the development and commercialization of insecticide products. It develops a patent-protected product platform based on a naturally occurring class of chemicals known as beta-triketones. Its product includes Qcide and Flavocid. Its target applications include agriculture, public health, and consumer and animal health. The firm operates in one business segment namely the conduct of research and development activities in the discovery of novel insecticides.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ASX:BGT has been successfully added to your 